



Institutional Biosafety Committee
Meeting Minutes

Date: 07/21/2025 Start time: 3:00pm (ET) End time: 5:00pm (ET)

Advarra IBC meetings are closed to the public to protect confidential and proprietary information as outlined in the Advarra IBC standard operating procedures.

Chair: Paul Gulig

Voting Members Present: Dan Eisenman (Committee Member), Darlene Ward (Committee Member), Nichole Tower (Committee Member), Alain Houmeidan (Committee Member), Jackie Lomeli (Committee Member), Adam Soloff (Committee Member), Begoña Comin-Anduix (Committee Member), Aparupa Sengupta (Committee Member), Amanda Garner (Community Member), Amita Pathak (Community Member)

Other Persons Present: [REDACTED]

Conflict of Interest: The IBC Chair queried the IBC to identify any potential conflicts of interest and requested that any potential conflicts of interest be disclosed to the IBC. The IBC Chair then reminded the IBC that if any potential conflicts of interest were identified as the meeting progressed, disclosure would need to occur at that time. Identified potential conflict of interest: Yes No

Study Summary Information for Minutes			
Protocol #	[REDACTED]	IBC Study Submission ID #	PROTO202400100
Study Title	Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity in Relation to the Product Attributes of [REDACTED] Vaccine in Adults ≥50 to <65 Years of Age		
Agent	lipid nanoparticle encapsulated mRNA		
Agent Characteristics	lipid nanoparticle encapsulated mRNA		
rDNA Category	III-C-1		
Description of Recombinant Nucleic Acid Sources	<ul style="list-style-type: none"> • mRNA encoding [REDACTED] • mRNA encoding [REDACTED] 		

Description of Genetically Modified Microbes or Vectors	<ul style="list-style-type: none"> N/A 				
Description of Transgene Expression	<ul style="list-style-type: none"> mRNA encoding [REDACTED] mRNA encoding [REDACTED] 				
Risk Assessment of Procedures	<ul style="list-style-type: none"> Delivered intramuscularly <ul style="list-style-type: none"> Sharps Safety Standard Precautions All materials disposed of as biohazardous waste 				
Site Information					
Site Name	DM Clinical Research (13406) - Tomball, TX	IBC Site Submission ID #	AMEND202500973		
PI Name	Vicki Miller				
Site Biosafety Level	BSL2				
Staff Training Verified by PI Signed SOP	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No				
Amendment Summary	Location Change				
Motions, Votes, and Committee's Decision					
Motion: Approve					
Conditions: N/A					
Motion	First: [REDACTED]		Second: [REDACTED]		
Votes	For: 11	Against: 0	Recused: 0	Absent: 0	Abstained: 0

Chair Signature

Approved by Chair:

Name: Paul A. Gulig, Ph.D

Date: 2025/07/30